Best AAV / Gene Therapy CDMOs in Europe

· updated as new inspection, certificate, and trial data enters the platform
← All AAV CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China
28
CDMOs tracked
28
Fully scored
9
With FDA records
35
FDA inspections
170
EMA/MHRA GMP certs
2
Warning letters

For European-manufactured aav / gene therapy programs, Takeda, AGC Biologics, and Oxford Biomedica lead CDMO Signal's ranking of aav / gene therapy CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 55 scored aav / gene therapy CDMOs to 5 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Adeno-associated virus (AAV) is the dominant delivery platform for in vivo gene therapy, from rare-disease programs to larger systemic indications. Rising demand has pushed CDMOs to scale suspension processes and tighten full/empty capsid analytics.

Selecting an AAV CDMO hinges on serotype experience, suspension vs adherent platform, full/empty capsid separation, and a proven regulatory record. The rankings below score each manufacturer on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 11 NAI (no action), 22 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (42), Denmark (35), United States (29), Germany (21), Italy (13).

Last updated 2026-09-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
TK
Takeda
Boston, MA · Zurich, CH
 81.9 99.6 4 insp · 18 GMP — 100 programs
2
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
 78.6 100.0 2 insp · 23 GMP Available 2 programs
3
OX
Oxford Biomedica
Oxford, United Kingdom
 76.2 100.0 0 insp · 13 GMP Available 7 programs
4
Lonza
Basel, Switzerland
 76.0 95.7 2 insp · 8 GMP — 1 programs
5
RT
ReiThera
Rome, IT
 71.1 100.0 0 insp · 4 GMP — 1 programs
6
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
 90.9 98.3 8 insp · 11 GMP Limited 0 programs
7
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
 88.0 100.0 0 insp · 3 GMP — 0 programs
8
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
 84.8 100.0 0 insp · 23 GMP Expanding 0 programs
9
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
 80.2 97.1 4 insp · 8 GMP — 0 programs
10
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
 79.5 100.0 — Available 0 programs
11
AA
Ascend Advanced Therapies
London, United Kingdom
 78.1 100.0 0 insp · 1 GMP — 0 programs
12
NG
NecstGen
Leiden, NL
 78.1 100.0 0 insp · 1 GMP — 0 programs
13
ET
Exothera
Jumet, BE
 78.1 100.0 0 insp · 4 GMP — 0 programs
14
PG
ProBioGen
Berlin, DE
 78.1 100.0 0 insp · 4 GMP — 0 programs
15
CE
Celonic
Basel, Switzerland
 78.1 100.0 0 insp · 1 GMP — 0 programs
16
XP
eXmoor Pharma
Bristol, United Kingdom
 78.1 100.0 0 insp · 1 GMP — 0 programs
17
AD
Advent Bioservices
London, United Kingdom
 78.1 100.0 0 insp · 2 GMP — 0 programs
18
BV
Biovian
Turku, Finland
 78.0 99.8 1 insp · 4 GMP — 0 programs
19
VG
Viralgen Vector Core
San Sebastián, Spain
 76.8 100.0 0 insp · 4 GMP Available 0 programs
20
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
 74.0 — — — 0 programs
21
Catalent
Bagsværd, Denmark (operating under Novo Holdings; key US DP site: Bloomington, IN)
 73.1 74.9 12 insp · 37 GMP — 0 programs
22
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
 73.1 74.9 1 insp · 0 GMP Available 0 programs
23
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
 73.0 95.7 1 insp · 0 GMP Limited 0 programs
24
RA
Recipharm Advanced Bio
Stockholm, Sweden
 63.0 — — — 0 programs
25
AB
Asklepios BioPharmaceutical (AskBio)
Research Triangle, NC · San Sebastian, ES
 61.8 — — — 10 programs
26
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
 59.0 — — — 0 programs
27
AM
Anemocyte
Gerenzano, IT
 59.0 — — — 0 programs
28
CV
CEVEC Pharmaceuticals
Cologne, DE
 56.5 — — — 0 programs
How we score CDMOs →

What to evaluate in a AAV / Gene Therapy CDMO

Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

AAV / Gene Therapy CDMOs — Frequently Asked Questions

Who are the top AAV / Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked AAV / Gene Therapy CDMOs include Takeda, AGC Biologics, Oxford Biomedica. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many AAV / Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 9 AAV / Gene Therapy CDMOs with FDA inspection records and 170 EMA/MHRA GMP certificates across the group.
What should I look for in an AAV CDMO?
Look for serotype experience, a scalable suspension platform, strong full/empty capsid analytics, and a clean FDA and EMA/MHRA record. Match validated bioreactor scale to your dose and indication.
What's the difference between AAV and lentiviral CDMOs?
AAV is non-integrating and produced at higher volumes for in vivo gene therapy. Lentivirus integrates into the genome, is made under BSL-2 with RCL testing, and is used mainly for ex vivo cell engineering like CAR-T.
Related modalities
Lentiviral Vector CDMOs Gene Editing CDMOs Plasmid DNA CDMOs
Other Modalities
CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector